Gilead, Vertex initiated as new big biotech buys at Citi
Citi initiates coverage of Gilead Sciences and Vertex Pharmaceuticals at buy in the large U.S. biotech sector. Read more here.
Ligand to Present at Stifel 2024 Healthcare Conference
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief ...
ZNetwork on MSN3h
Inconvenient Question: Science Is Gifting Us New HIV Prevention Tools But Is It Expanding Choices For The People?
Any new HIV prevention method is not meant to sit on the shelf but to be used by the people who need it to protect themselves ...
The Globe and Mail15h
S&P Futures Soar as Trump Wins U.S. Presidency, FOMC Meeting on Tap
December S&P 500 E-Mini futures (ESZ24) are trending up +2.24% this morning after Republican Donald Trump won the U.S. presidential election. Donald Trump was elected the 47th president of the United ...
Le Lézard14h
Meiji Seika Pharma Announces Investment in ARCALIS, Inc.
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan, President and Representative Director: Daikichiro Kobayashi; hereinafter referred to as "Meiji Seika Pharma") today announced its investment ...
Citi initiates coverage on 5 new biotech stocks
Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and ...